ZTALMY
Total Payments
$679,494
Transactions
2,599
Doctors
1,032
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $124,723 | 917 | 533 |
| 2023 | $467,131 | 1,286 | 647 |
| 2022 | $87,641 | 396 | 242 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $285,157 | 50 | 42.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $223,214 | 151 | 32.9% |
| Food and Beverage | $82,260 | 2,256 | 12.1% |
| Consulting Fee | $55,185 | 17 | 8.1% |
| Travel and Lodging | $33,406 | 113 | 4.9% |
| Education | $272.20 | 12 | 0.0% |
Payments by Type
General
$394,337
2,549 transactions
Research
$285,157
50 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus | Marinus Pharmaceuticals, Inc. | $285,157 | 0 |
Top Doctors Receiving Payments for ZTALMY — Page 42
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Neurology | Tuscon, AZ | $14.22 | 1 |
| , MD | Physical Medicine & Rehabilitation | Morristown, NJ | $14.21 | 1 |
| , M.D | Neurological Surgery | Morristown, NJ | $14.21 | 1 |
| , MD | Pediatrics | Bingham Farms, MI | $14.05 | 1 |
| , NP | Pediatrics | Portland, OR | $13.54 | 1 |
| , MD | Pediatrics | Portland, OR | $13.54 | 1 |
| , NP | Registered Nurse | Rocklin, CA | $13.44 | 1 |
| , M.D | Pediatrics | Newport, TN | $12.08 | 1 |
Ad
Manufacturing Companies
- Marinus Pharmaceuticals, Inc. $679,494
Product Information
- Type Drug
- Total Payments $679,494
- Total Doctors 1,032
- Transactions 2,599
About ZTALMY
ZTALMY is a drug associated with $679,494 in payments to 1,032 healthcare providers, recorded across 2,599 transactions in the CMS Open Payments database. The primary manufacturer is Marinus Pharmaceuticals, Inc..
Payment data is available from 2022 to 2024. In 2024, $124,723 was paid across 917 transactions to 533 doctors.
The most common payment nature for ZTALMY is "Unspecified" ($285,157, 42.0% of total).
ZTALMY is associated with 1 research study, including "A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus" ($285,157).